...
首页> 外文期刊>OncoTargets and therapy >Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics
【24h】

Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics

机译:非转移性结直肠癌掺入血液天然生物标志物和临床特征的预后NOM图

获取原文
           

摘要

Background: There is a large difference in postoperative survival in patients with non-metastatic colorectal cancer. We aimed to develop nomograms incorporating both hematological biomarkers and clinical characteristics to predict overall survival (OS) in patients with radical surgery for non-metastatic colorectal cancer. Methods: A retrospective analysis was performed on date from 508 patients who underwent radical resection of colorectal cancer at the Affiliated Tumor Hospital of Guangxi Medical University from December 2011 to December 2015. Simple random sampling was performed by dividing these patients into a training set (n=355) and validation set(n=153), which yielded a 7:3 ratio in the sample sizes between these groups. Based on COX regression analysis of the results from the training cohort, a nomogram was developed to predict the three-year and five-year overall survival rate, and internal verification was also performed. The nomogram prediction accuracy and discriminating ability were evaluated by Harrell’s C-index (C-index), calibration curves and were compared with the colorectal cancer TNM staging system. Results: We found that age, degree of differentiation, T stage, N stage, neurological invasion, neutrophils, monocytes, HGB, and LDH were independent risk factors for predicting OS in patients with colorectal cancer. In the training cohort, the C index was 0.796 (95% CI: 0.761– 0.831). In the validation cohort, the C index was 0.671 (95% CI: 0.656– 0.686).The nomogram showed a stronger predictive ability than did TNM staging. Decision curve analysis showed that the nomogram had value in terms of clinical application. Conclusion: Our nomogram combined hematological biomarkers and clinical characteristics and was highly effective in predicting OS in patients with non-metastatic colorectal cancer. Hence, our nomogram may provide a reference tool for clinicians to guide individualized treatment and follow-ups for patients with colorectal cancer.
机译:背景:非转移结直肠癌患者术后生存率存在很大差异。我们旨在开发含有血液学生物标志物的载体和临床特征,以预测非转移性结直肠癌自由基手术患者的整体存活(OS)。方法:从2011年12月到2015年12月,从508名在广西医科大学附属肿瘤医院接受直肠切除结直肠癌的508名患者的患者进行回顾性分析。通过将这些患者划分为培训组来进行简单的随机抽样(n = 355)和验证集(n = 153),其在这些组之间的样本尺寸中产生7:3的比率。根据培训队列结果的COX回归分析,制定了一个墨顶图,以预测三年和五年的整体生存率,并进行内部核查。通过Harrell的C-Index(C-Index),校准曲线评估了NOM图预测准确度和辨别能力,并与结肠直肠癌TNM分期系统进行了比较。结果:我们发现,年龄,分化程度,T阶段,N阶段,神经侵袭,中性粒细胞,单核细胞,HGB和LDH是用于预测结直肠癌患者OS的独立危险因素。在培训队列中,C指数为0.796(95%CI:0.761- 0.831)。在验证队列中,C指数为0.671(95%CI:0.656- 0.686)。NOM图显示出比TNM分期更强的预测能力。决策曲线分析表明,NOM图在临床应用方面具有价值。结论:我们的拓图组合血液天然血管科和临床特征,在非转移结直肠癌患者预测OS中具有高度有效的。因此,我们的纳米图可以为临床医生提供参考工具,用于指导对结直肠癌患者的个体化治疗和随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号